What the WHI study actually found, and what changed since
A single 2002 trial caused a 20-year, worldwide drop in HRT use. The headline findings were real, but the picture has been substantially reinterpreted since: most people, including many clinicians, are still working from the 2002 version. Here's the full story, not the panic or the overcorrection.
The trial landscape
| Trial | N | What it found | Source |
|---|---|---|---|
| WHI (2002, original) | 16,608 | Combined estrogen+progestin, avg. age 63, mean follow-up 5.2 yrs. Breast cancer HR 1.26, coronary heart disease HR 1.29, stroke HR 1.41. Per 10,000 person-years: 8 more breast cancers, 7 more CHD events, 8 more strokes; offset partly by 6 fewer colorectal cancers, 5 fewer hip fractures. The separate estrogen-only arm (for women post-hysterectomy) did not show increased breast cancer risk. | Rossouw 2002 |
| WHI reanalysis (timing hypothesis) | 16,608 | Pooled by age: mortality HR 0.69 (favorable) for ages 50-59 vs. unfavorable trend at older ages. Excess adverse events per 10,000 women/yr: just 12 for ages 50-59 vs. 38 for ages 70-79 (combined therapy); estrogen-alone showed 19 fewer cases for ages 50-59 vs. 51 excess for ages 70-79. | Manson JAMA 2013 |
| KEEPS | 727 | Recently-menopausal women (42-58), low CV risk, 4 years: no acceleration of arterial plaque buildup and no increase in cardiovascular events on oral or transdermal estrogen vs. placebo, reassuring safety in this younger population, supporting the timing hypothesis. (Underpowered for hard CV endpoints like heart attack.) | Harman 2014 |
What this means in plain language
The scary numbers were relative risk, not absolute risk
A "26% increased breast cancer risk" sounds alarming. In absolute terms, WHI found 8 additional breast cancers per 10,000 women per year on combined HRT: a real but far smaller-sounding number than the relative-risk headline that drove two decades of fear. Both framings are true; only one made headlines.
WHI's average participant doesn't look like today's typical HRT candidate
WHI enrolled women averaging 63 years old, many a decade or more past menopause onset. Most women today start HRT for hot flashes in their late 40s to early 50s. The reanalysis found this age gap matters enormously: the risk profile for a 52-year-old starting HRT near menopause onset looks very different from a 63-year-old starting it a decade later.
The February 2026 FDA change isn't "HRT is risk-free now"
The FDA removed boxed-warning language from several HRT products in early 2026, and ACOG/NAMS supported this specifically for low-dose vaginal estrogen. But both societies were explicit: systemic HRT (pills, patches, gels for hot flashes) still carries individualized risk that warrants real counseling. The label change reflects updated science, not a green light to skip that conversation.
Decision framework
| Your priority | What the evidence supports |
|---|---|
| "Is HRT safe for me?" | Depends heavily on age and time since menopause, not a single yes/no answer. Most favorable within 10 years of onset or under 60. |
| Understanding the WHI scare | This page: the gap between what WHI found and what most people believe it found is large and well-documented. |
| Format choice (pill vs. patch vs. gel) | Transdermal (patch/gel) shows essentially no elevated blood-clot risk vs. placebo (RR ~1.0); oral estrogen does (RR ~1.9): a real, well-replicated difference. |
| Uterus-intact vs. post-hysterectomy | Matters for the evidence itself: WHI's estrogen-only arm (post-hysterectomy candidates) did not show the increased breast-cancer signal seen in the combined estrogen+progestin arm. |
Sources
- Rossouw JE, et al. Risks and Benefits of Estrogen Plus Progestin (WHI). JAMA. 2002.
- Manson JE, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of WHI. JAMA. 2013.
- The Menopause Society (NAMS): 2022 Hormone Therapy Position Statement
- Harman SM, et al. KEEPS Trial. Annals of Internal Medicine. 2014.
- AJMC: FDA to Remove Black Box Warnings From HRT, Debate Ensues (Feb 2026)
- ACOG: Elimination of the Black Box Warning on Menopausal Hormone Therapy
- ACOG Committee Opinion: Route of Administration and VTE Risk
See how 9 providers score
Every provider scored on evidence-based prescribing, rating, insurance support, and menopause-specific specialization.
View the scores